高丽,王俊伟,杨宇辉

• 1:三亚中心医院(海南省第三人民医院)皮肤科
• 2:河南科技大学第二附属医院皮肤科

摘要(Abstract)：

目的 研究寻常性银屑病马拉色菌感染与血清P物质(SP)、肿瘤坏死因子-α(TNF-α)及皮肤人β防御素2(HBD-2)mRNA表达水平的关系。方法 回顾性收集2020年1月-2022年6月河南科技大学第二附属医院收治的80例寻常性银屑病马拉色菌感染患者为感染组，随机选取同期医院收治的86例寻常性银屑病未发生马拉色菌感染患者为未感染组，统计两组一般资料及血清SP、TNF-α及皮肤HBD-2 mRNA表达水平；感染组患者根据不同病情严重程度分为轻、中和重度组，分别为28、27和25例，比较不同病情严重程度感染组患者马拉色菌密度，采用Spearman相关性分析马拉色菌密度与寻常性银屑病患者病情严重程度相关性。结果 感染组血清SP、TNF-α及皮肤HBD-2 mRNA表达水平高于未感染组(P<0.05)。轻、中、重度组马拉色菌密度为+呈降低趋势，马拉色菌密度为+++呈升高趋势，组间比较，差异具有统计学意义(P<0.05)。Spearman相关性分析显示，马拉色菌密度与寻常性银屑病患者病情严重程度呈正相关关系(r=0.604,P=0.003)。结论 马拉色菌感染可引起寻常性银屑病患者外周血SP、TNF-α及皮肤HBD-2 mRNA表达水平变化及病情进展，同时马拉色菌感染与寻常性银屑病患者病情严重程度明显相关。

关键词(KeyWords)： 寻常性银屑病;马拉色菌;P物质;肿瘤坏死因子-α;人β防御素2;mRNA

Abstract:

Keywords:

基金项目(Foundation): 河南省医学科技攻关计划联合共建基金资助项目(LHGL20191648)

作者(Author): 高丽,王俊伟,杨宇辉

参考文献(References)：

• [1] Pezzolo E,Cazzaniga S,Colombo P,et al.Psoriasis incidence and lifetime prevalence:suggestion for a higher mortality rate in older age-classes among psoriatic patients compared to the general population in Italy[J].Acta Derm Venereol,2019,99(4):400-403.
• [2] 曾令斌，陆捷洁，吴伟伟，等.马拉色菌感染对寻常型银屑病患者血清SP、Th1/Th2有关因子的影响及与病情关联性[J].中国美容医学，2021,30(7):58-61.
• [3] 宋黎，唐懿，刘彦麟，等.马拉色菌毛囊炎47例皮肤镜特征分析[J].实用皮肤病学杂志，2021,14(4):214-216.
• [4] Chang J,Litvinov IV,Ly C,et al.Utilization of the psoriasis epidemiology screening tool (PEST):a risk stratification strategy for early referral of psoriatic arthritis patients to minimize irreversible erosive joint damage[J].J Cutan Med Surg,2022,26(6):600-603.
• [5] 田阳洋，刘书娜，周明伟，等.中重度痤疮患者马拉色菌和毛囊螨感染情况分析[J].中国实验诊断学，2022,26(1):60-61.
• [6] Mease PJ,Smolen JS,Behrens F,et al.A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na?倞ve patients with active psoriatic arthritis:24-week results of a randomised,open-label,blinded-assessor trial[J].Ann Rheum Dis,2020,79(1):123-131.
• [7] Engin B,Tanakol A,Bulut H,et al.Changes in serumTNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments[J].Int J Dermatol,2020,59(2):207-215.
• [8] Uzuncakmak TK,Karadag AS,Ozkanli S,et al.Alteration of tissue expression of human beta defensin-1 and human beta defensin-2 in psoriasis vulgaris following phototherapy[J].Biotech Histochem,2020,95(4):243-248.
• [9] 中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018简版)[J].中华皮肤科杂志，2019,52(4):223-230.
• [10] 涂亚庭.皮肤性病学[M].2版.北京：科学出版社，2009:73-76.
• [11] 张绚辉，张玲，曾海燕，等.重楼凉血克银方内服和外用对银屑病血热风盛证患者IL-23/IL-17轴的调节作用[J].环球中医药，2020,13(12):2167-2169.
• [12] 刘晓明.国内外最新银屑病诊疗指南解读：疾病严重程度评估及生物制剂治疗[J].皮肤性病诊疗学杂志，2023,30(1):1-5.
• [13] Lada G,Chinoy H,Heal C,et al.Depression and suicidality in patients with psoriasis and the role of psoriatic arthritis:across-sectional study in a tertiary setting[J].J Acad Consult Liaison Psychiatry,2022,63(4):372-383.
• [14] Gavra H,Tirosh I,Spielman S,et al.Validation of the psoriasis epidemiology screening tool (PEST) and the new early arthritis for psoriatic patients (EARP) in pediatric population:pilot study[J].Clin Rheumatol,2022,41(4):1125-1130.
• [15] Park SM,Kim GW,Kim HS,et al.Characteristics of pruritus according to morphological phenotype of psoriasis and association with neuropeptides and interleukin-31[J].Ann Dermatol,2020,32(1):1-7.
• [16] Amalia SN,Uchiyama A,Baral H,et al.Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system[J].J Dermatol Sci,2021,101(1):58-68.
• [17] Dapavo P,Siliquini N,Mastorino L,et al.Efficacy,safety,and drug survival of IL-23,IL-17,and TNF-alpha inhibitors for psoriasis treatment:a retrospective study[J].J Dermatolog Treat,2022,33(4):2352-2357.
• [18] Botelho KP,Pontes MAA,Rodrigues CEM,et al.Prevalence of metabolic syndrome among patients with psoriasis treated with TNF inhibitors and the effects of anti-TNF therapy on their lipid profile:a prospective cohort study[J].Metab Syndr Relat Disord,2020,18(3):154-160.
• [19] Blome C,von Stulpnagel CC,Augustin M,et al.Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index:development and preliminary validation of a 10-item short form[J].Br J Dermatol,2022,187(4):588-589.
• [20] Gonzalez-Cantero A,Ortega-Quijano D,Alvarez-Diaz N,et al.Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis:a systematic review and meta-analysis of randomized placebo-controlled trials[J].J Invest Dermatol,2021,141(10):2402-2411.
• [21] Cohen JN,Bowman S,Laszik ZG,et al.Clinicopathologic overlap of psoriasis,eczema,and psoriasiform dermatoses:a retrospective study of T helper type 2 and 17 subsets,interleukin 36,and β-defensin 2 in spongiotic psoriasiform dermatitis,sebopsoriasis,and tumor necrosis factor α inhibitor-associated dermatitis[J].J Am Acad Dermatol,2020,82(2):430-439.